Healthcare Biz Report: OraSure’s Home HIV TEST, Roche’s Lucentis OKAYED

A new home test for HIV is given credit for OraSure Technologies, Inc.(NASDAQ:OSUR) getting initial coverage by Jefferies with a Buy, and a price target of $14. The research company points to the revenue growth potential of the test kit, and also that shares are trading at a notable discount to its projected 2013 revenue forecast.

Don’t Miss: PetSmart Second Quarter Earnings Sneak Peek.

Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) move up again on Friday on word that the firm’s board okayed an increase in its stock repurchase program of as much as $100 million, which is decidedly up compared to its previously authorized $25 million.

Roche’s (RHHBY) Lucentis wins FDA approval. Marketed by Roche’s Genentech, the medication is indicated for the treatment of diabetic macular edema, which is a sight-threatening eye disease that occurs in people suffering from diabetes.

Friday Icahn news: The activist investor now wants a Delaware Court to permit him to publicize documents concerning change of corporate control at Forest Laboratories, Inc. (NYSE:FRX). The documents were released to Icahn on August 6th, and cover licensing agreements with other drug producers. One of them describes an embedded “poison pill” designed to put off any potential FRX takeover. Icahn wants these matters publicized so that investors would know about the agreements prior to the company’s annual meeting on August 15.

Don’t Miss: Is DuPont’s Stock a BUY?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.